Patrick A. Singleton, Ph. D. - 2007 Young Investigator Award
"Hyaluronan (HA) Regulation of Tumor-associated Angiogenesis"
Awarded a $50,000 2007 Young Investigator Award
Angiogenesis or the formation of new blood vessels is important in the growth and metastatic potential of various cancers. Therefore, recent therapeutic interventions for the inhibition of cancer progression include drugs that target both tumor growth and angiogenesis. However, the cost of these drugs are often high and there are significant side effects. Therefore, the discovery of a potent, cost effective, anti-angiogenic agent with minimal side effects would be of immense importance in cancer therapy. We have exciting preliminary data to suggest that high molecular weight hyaluronan (HMW-HA), the major glycosaminoglycan in the body, inhibits tumor-associated angiogenesis through CD44 isoform-specific signaling and inhibition of hyaluronidase and HABP2 activity. Therefore, HMW-HA can potentially be used as a novel cost effective cancer treatment. As HMW-HA occurs naturally in the body and is currently used in the treatment of skin and joint disorders, one can anticipate minimal side effects.
"Thanks to the hard work, commitment, and compassion of scientists, researchers, and organizations like the Cancer Research Foundation, there is renewed hope for discovering better treatments and eventually a cure for cancer.
I commend all of you for your outstanding contributions to the field of cancer research. For five decades, your commitment to the crusade against cancer has given hope and comfort to people across the nation."
Former President of the United States
May 05, 1997